Ovarian cancer statistics, 2018
2018/05/29 by Lindsey A. Torre, Britton Trabert, Carol DeSantis +7 · 42 citations
Medicine · Biochemistry, Genetics and Molecular Biology · #Ovarian cancer diagnosis and treatment #BRCA gene mutations in cancer #Cancer Risks and Factors
paper · pdf · doi:10.3322/caac.21456
Abstract
In 2018, there will be approximately 22,240 new cases of ovarian cancer diagnosed and 14,070 ovarian cancer deaths in the United States. Herein, the American Cancer Society provides an overview of ovarian cancer occurrence based on incidence data from nationwide population-based cancer registries and mortality data from the National Center for Health Statistics. The status of early detection strategies is also reviewed. In the United States, the overall ovarian cancer incidence rate declined from 1985 (16.6 per 100,000) to 2014 (11.8 per 100,000) by 29% and the mortality rate declined between 1976 (10.0 per 100,000) and 2015 (6.7 per 100,000) by 33%. Ovarian cancer encompasses a heterogenous group of malignancies that vary in etiology, molecular biology, and numerous other characteristics. Ninety percent of ovarian cancers are epithelial, the most common being serous carcinoma, for which incidence is highest in non-Hispanic whites (NHWs) (5.2 per 100,000) and lowest in non-Hispanic blacks (NHBs) and Asians/Pacific Islanders (APIs) (3.4 per 100,000). Notably, however, APIs have the highest incidence of endometrioid and clear cell carcinomas, which occur at younger ages and help explain comparable epithelial cancer incidence for APIs and NHWs younger than 55 years. Most serous carcinomas are diagnosed at stage III (51%) or IV (29%), for which the 5-year cause-specific survival for patients diagnosed during 2007 through 2013 was 42% and 26%, respectively. For all stages of epithelial cancer combined, 5-year survival is highest in APIs (57%) and lowest in NHBs (35%), who have the lowest survival for almost every stage of diagnosis across cancer subtypes. Moreover, survival has plateaued in NHBs for decades despite increasing in NHWs, from 40% for cases diagnosed during 1992 through 1994 to 47% during 2007 through 2013. Progress in reducing ovarian cancer incidence and mortality can be accelerated by reducing racial disparities and furthering knowledge of etiology and tumorigenesis to facilitate strategies for prevention and early detection. CA Cancer J Clin 2018;68:284-296. © 2018 American Cancer Society.
Citations
Cited by
- Expanding the Paradigm for Cardiovascular Palliative Care
- Mucinous Ovarian Carcinoma
- Screening and prevention of ovarian cancer
- Utilizing Serum-Derived Lipidomics with Protein Biomarkers and Machine Learning for Early Detection of Ovarian Cancer in the Symptomatic Population
- Ovarian cancer risk reduction by salpingectomy during non-gynaecological surgery: scoping review
- FOXM1: A small fox that makes more tracks for cancer progression and metastasis
- Myeloid cell networks govern re-establishment of original immune landscapes in recurrent ovarian cancer
- Discovery of differentially expressed proteins for CAR-T therapy of ovarian cancers with a bioinformatics analysis
- Triple checkpoint blockade of PD-1, Tim-3, and Lag-3 enhances adoptive T cell immunotherapy in a mouse model of ovarian cancer
- Multi-omics analysis reveals the attenuation of the interferon pathway as a driver of chemo-refractory ovarian cancer
- Epithelial characteristics of ovarian clear cell carcinoma at single-cell resolution
- MYC and HSF1 Cooperate to Drive Sensitivity to Polo-like Kinase 1 Inhibitor Volasertib in High-grade Serous Ovarian Cancer
- Adenosine drives suppression of CD16low NK cell responses against HGSC via NKG2A:hLA-E interactions
- Emerging roles of suppressor of cytokine signaling 3 in human cancers
- Nanoscale structural alterations in cancer cells to assess anti-cancerous drug effectiveness in cancer treatment using TEM imaging
- Combining multiple biomarkers to linearly maximize the diagnostic accuracy under ordered multi-class setting
- Anti-cancer effects of benzimidazole derivative BNZ-111 on paclitaxel-resistant ovarian cancer
- Cell Origins of High-Grade Serous Ovarian Cancer. [europepmc]
- Experimental Evidence of the Antitumor, Antimetastatic and Antiangiogenic Activity of Ellagic Acid. [europepmc]
- Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study. [europepmc]
- Ovarian cancer in the world: epidemiology and risk factors. [europepmc]
- Berberine in combination with cisplatin induces necroptosis and apoptosis in ovarian cancer cells. [europepmc]
- Exosomes promote pre-metastatic niche formation in ovarian cancer. [europepmc]
- Role of miRNA-Regulated Cancer Stem Cells in the Pathogenesis of Human Malignancies. [europepmc]
- Ovarian cancer cell-secreted exosomal miR-205 promotes metastasis by inducing angiogenesis. [europepmc]
- The microbiome and gynaecological cancer development, prevention and therapy. [europepmc]
- Randomized Phase II Trial of Nivolumab Versus Nivolumab and Ipilimumab for Recurrent or Persistent Ovarian Cancer: An NRG Oncology Study. [europepmc]
- Therapeutic Potential of Combining PARP Inhibitor and Immunotherapy in Solid Tumors. [europepmc]
- Integrated Proteomic and Glycoproteomic Characterization of Human High-Grade Serous Ovarian Carcinoma. [europepmc]
- Immunotherapy for Ovarian Cancer: Adjuvant, Combination, and Neoadjuvant. [europepmc]
- Updates and New Options in Advanced Epithelial Ovarian Cancer Treatment. [europepmc]
- CA125 and Ovarian Cancer: A Comprehensive Review. [europepmc]
- PARP inhibition promotes ferroptosis via repressing SLC7A11 and synergizes with ferroptosis inducers in BRCA-proficient ovarian cancer. [europepmc]
- Co-evolution of matrisome and adaptive adhesion dynamics drives ovarian cancer chemoresistance. [europepmc]
- The role of lncRNAs and circRNAs in the PD-1/PD-L1 pathway in cancer immunotherapy. [europepmc]
- Extracellular vesicles in ovarian cancer chemoresistance, metastasis, and immune evasion. [europepmc]
- RNA demethylase ALKBH5 in cancer: from mechanisms to therapeutic potential. [europepmc]
- Longitudinal single-cell RNA-seq analysis reveals stress-promoted chemoresistance in metastatic ovarian cancer. [europepmc]
- Role of main RNA modifications in cancer: N 6 -methyladenosine, 5-methylcytosine, and pseudouridine. [europepmc]
- Worldwide Burden, Risk Factors, and Temporal Trends of Ovarian Cancer: A Global Study. [europepmc]
- The RING finger protein family in health and disease. [europepmc]
- Treatment With Niraparib Maintenance Therapy in Patients With Newly Diagnosed Advanced Ovarian Cancer: A Phase 3 Randomized Clinical Trial. [europepmc]
Related